No Data
No Data
Express News | Rodman & Renshaw Reiterates Buy on Cognition Therapeutics, Maintains $14 Price Target
Express News | Cognition Therapeutics to Present Phase 2 SHINE Study of CT1812 In Mild-to-Moderate Alzheimer's Disease At Alzheimer's Association's International Conference
Results From Cognition Therapeutics' Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's Disease Accepted for Presentation at AAIC
Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation
Chardan Research Initiates Cognition Therapeutics With Buy Rating, $11 Price Target
Cognition Therapeutics (CGTX) has an average buy rating and a price target range of $5 to $11, according to analysts polled by Capital IQ. Price: 1.9200, Change: +0.09, Percent Change: +4.92
Cognition Therapeutics Price Target Announced at $11.00/Share by Chardan Capital
Cognition Therapeutics Price Target Announced at $11.00/Share by Chardan Capital
No Data